Drug and Therapeutics Bulletin 2004;42:49-52; doi:10.1136/dtb.2004.42749
Copyright © 2004 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

New oral drugs for erectile dysfunction

Relevant BNF section: 7.4.5

In 1998, we concluded that sildenafil (Viagra - Pfizer Ltd), a selective phosphodiesterase type 5 inhibitor, appeared to offer advantages over other medical approaches for erectile dysfunction in terms of ease of administration and cost.1 Oral drug treatment is now widely advocated as first-line therapy for erectile dysfunction,2 except where the cause is clearly psychological. In the past 4 years, three more oral preparations have been licensed in the UK for the treatment of men with erectile dysfunction. A sublingual preparation of the dopaminergic agonist {blacktriangledown}apomorphine (Uprima - Abbott Laboratories Ltd) is the first centrally acting drug to be licensed. {blacktriangledown}Tadalafil (Cialis - Eli-Lilly) and {blacktriangledown}vardenafil (Levitra - Bayer PLC) are phosphodiesterase type 5 inhibitors. Here we review the place of these preparations for men with erectile dysfunction.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2004 BMJ Publishing Group Ltd.